CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SONODRUGS develops innovative drug delivery technologies using nanomedicine for localized treatment of cancer and cardiovascular diseases. It focuses on ultrasound-triggered drug release to improve therapeutic outcomes and reduce side effects.
The demographic changes in Europe towards an aging society will coincide with increasing morbidity of the population.
European citizens need improved access to state-of-the-art medical care especially in oncology and cardiology, while keeping expenditures on healthcare affordable.
New therapeutic options such as externally triggered local drug release at the diseased area hold promise to solve urgent medical needs: improved treatment with reduced side effects, fewer burdens to the patient and fa…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, HAMBURG
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Germany, LUDWIGSHAFEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
France, Paris
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Cyprus, Nicosia
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
